Skip to main content

40 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

  1. Messinger JW, et al. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-­5 and schizophrenia research. Clin Psychol Rev 2011; 31:161–168.
  2. Foussias G, et al. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. J Psychopharmacol 2015; 29:116–126.
  3. Strauss GP, et al. Reconsidering the latent structure of negative symptoms in schizophrenia: a review of evidence supporting the 5 consensus domains. Schizophr Bull 2019; 45:725–729.
  4. Rucci P, et al. The structure stability of negative symptoms: longitudinal network analysis of the Brief Negative Symptom Scale in people with schizophrenia. BJPsych Open 2023; 9:e168.
  5. Carpenter WT. The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 1996; 168:17–22.
  6. Galderisi S, et  al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 2013; 23:196–204.
  7. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 2007; 33:1013–1022.
  8. Rabinowitz J, et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012; 137:147–150.
  9. Barnes TR, et al. How to distinguish between the neuroleptic-­induced deficit syndrome, depression and disease-­related negative symptoms in schizophrenia. Int Clin Psychopharmacol 1995; 10 Suppl 3:115–121.
  10. Veerman SRT, et al. Treatment for negative symptoms in schizophrenia: a comprehensive review. Drugs 2017; 77:1423–1459.
  11. Rammou A, et  al. Negative symptoms in first-­episode psychosis: clinical correlates and 1-­year follow-­up outcomes in London Early Intervention Services. Early Interv Psychiatry 2019; 13:443–452.
  12. Bobes J, et al. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010; 71:280–286.
  13. Correll CU, et al. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 2020; 16:519–534.
  14. Buckley PF, et al. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-­de-­sac? Acta Psychiatr Scand 2007; 115:93–100.
  15. Waddington JL, et al. Sequential cross-­sectional and 10-­year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995; 25:849–857.
  16. Melle I, et al. Prevention of negative symptom psychopathologies in first-­episode schizophrenia: two-­year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008; 65:634–640.
  17. Perkins DO, et al. Relationship between duration of untreated psychosis and outcome in first-­episode schizophrenia: a critical review and meta-­analysis. Am J Psychiatry 2005; 162:1785–1804.
  18. Aleman A, et al. Treatment of negative symptoms: where do we stand, and where do we go? Schizophr Res 2017; 186:55–62.
  19. Darbà J, et al. Efficacy of second-­generation-­antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-­analysis of randomized clinical trials. Rev Psiquiatr Salud Ment 2011; 4:126–143.
  20. Leucht S, et al. Second-­generation versus first-­generation antipsychotic drugs for schizophrenia: a meta-­analysis. Lancet 2009; 373:31–41.
  21. Erhart SM, et al. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull 2006; 32:234–237.
  22. Harvey RC, et al. A systematic review and network meta-­analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-­onset schizophrenia. CNS Drugs 2016; 30:27–39.
  23. Zhang JP, et al. Efficacy and safety of individual second-­generation vs. first-­generation antipsychotics in first-­episode psychosis: a systematic review and meta-­analysis. Int J Neuropsychopharmacol 2013; 16:1205–1218.
  24. Leucht S, et al. A meta-­analysis of head-­to-­head comparisons of second-­generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.
  25. Fusar-­Poli P, et al. Treatments of negative symptoms in schizophrenia: meta-­analysis of 168 randomized placebo-­controlled trials. Schizophr Bull 2015; 41:892–899.
  26. Németh G, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-­blind, controlled trial. Lancet 2017; 389:1103–1113.
  27. Ivanov SV, et al. Early clinical effects of novel partial D3/D2 agonist cariprazine in schizophrenia patients with predominantly negative symptoms (open-­label, non-­controlled study). Front Psychiatry 2021; 12:770592.
  28. Németh G, et al. Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-­ world study, and clinical cases. Expert Opin Pharmacother 2022; 23:1467–1468.
  29. Speller JC, et al. One-­year, low-­dose neuroleptic study of in-­patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpride v. haloperidol. Br J Psychiatry 1997; 171:564–568.
  30. Krause M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-­analysis. Eur Arch Psychiatry Clin Neurosci 2018; 268:625–639.
  31. Danion JM, et al. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999; 156:610–616.
  32. Leucht S, et al. Amisulpride, an unusual ‘atypical’ antipsychotic: a meta-­analysis of randomized controlled trials. Am J Psychiatry 2002; 159:180–190.
  33. Liang Y, et al. Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study. Neuropsychiatr Dis Treat 2017; 13:1703–1712.
  34. Zheng W, et  al. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-­analysis of randomized controlled trials. J Clin Psychopharmacol 2016; 36:628–636.

38 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 35. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-­analysis and meta-­regression analysis. World Psychiatry 2017; 16:77–89. 36. Earley W, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res 2019; 204:282–288. 37. Brasso C, et al. Efficacy of serotonin and dopamine activity modulators in the treatment of negative symptoms in schizophrenia: a rapid review. Biomedicines 2023; 11:921. 38. Howes O, et  al. Treating negative symptoms of schizophrenia: current approaches and future perspectives. Br J Psychiatry 2023; 223:332–335. 39. Siskind D, et al. Clozapine v. first-­ and second-­generation antipsychotics in treatment-­refractory schizophrenia: systematic review and meta-­ analysis. Br J Psychiatry 2016; 209:385–392. 40. Souza JS, et al. Efficacy of olanzapine in comparison with clozapine for treatment-­resistant schizophrenia: evidence from a systematic review and meta-­analyses. CNS Spectr 2013; 18:82–89. 41. Asenjo Lobos C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; (11):CD006633. 42. Oloyede E, et  al. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Ther Adv Psychopharmacol 2022; 12:20451253211066642. 43. Siwek M, et al. Cariprazine augmentation of clozapine in schizophrenia: a retrospective chart review. Front Pharmacol 2023; 14:1321112. 44. Kishi T, et al. Memantine add-­on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-­analysis. Psychopharmacology (Berl) 2017; 234:2113–2125. 45. Zheng W, et al. Adjunctive memantine for schizophrenia: a meta-­analysis of randomized, double-­blind, placebo-­controlled trials. Psychol Med 2018; 48:72–81. 46. Etchecopar-­Etchart D, et  al. Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-­analysis. EClinicalMedicine 2024; 69:102473. 47. Tiihonen J, et al. The efficacy of lamotrigine in clozapine-­resistant schizophrenia: a systematic review and meta-­analysis. Schizophr Res 2009; 109:10–14. 48. Veerman SR, et  al. Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry 2014; 47:185–194. 49. Oya K, et al. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-­analysis of randomized controlled trials. Hum Psychopharmacol 2014; 29:483–491. 50. Xiang YQ, et al. Adjunctive minocycline for schizophrenia: a meta-­analysis of randomized controlled trials. Eur Neuropsychopharmacol 2017; 27:8–18. 51. Weiser M, et al. The effect of minocycline on symptoms in schizophrenia: results from a randomized controlled trial. Schizophr Res 2019; 206:325–332. 52. Afshar H, et  al. Topiramate add-­on treatment in schizophrenia: a randomised, double-­blind, placebo-­controlled clinical trial. J Psychopharmacol 2009; 23:157–162. 53. Rummel C, et al. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006; (3):CD005581. 54. Kishi T, et al. Meta-­analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol 2014; 17:343–354. 55. Sepehry AA, et al. Selective serotonin reuptake inhibitor (SSRI) add-­on therapy for the negative symptoms of schizophrenia: a meta-­analysis. J Clin Psychiatry 2007; 68:604–610. 56. Singh SP, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-­analysis. Br J Psychiatry 2010; 197:174–179. 57. Barnes TR, et al. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-­blind, placebo-­controlled, randomised clinical trial. Health Technol Assess 2016; 20:1–46. 58. Galling B, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 2018; 137:187–205. 59. Helfer B, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-­analysis. Am J Psychiatry 2016; 173:876–886. 60. Zheng W, et  al. Adjunctive reboxetine for schizophrenia: meta-­analysis of randomized double-­blind, placebo-­controlled trials. Pharmacopsychiatry 2020; 53:5–13. 61. Karbalaee M, et al. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: a randomized, double-­blind, placebo-­controlled clinical trial. Schizophr Res 2023; 254:92–98. 62. Correll CU, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-­analytic evidence. JAMA Psychiatry 2017; 74:675–684. 63. Singh V, et al. Review and meta-­analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 2010; 13:257–271. 64. Sommer IE, et  al. Nonsteroidal anti-­inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-­analysis. J Clin Psychiatry 2012; 73:414–419. 65. Amiri A, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-­blind randomized placebo-­controlled study. Hum Psychopharmacol 2008; 23:79–86. 66. Bodkin JA, et al. Double-­blind, placebo-­controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 2005; 162:388–390.

Schizophrenia and related psychoses CHAPTER 1 67. Kelleher JP, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol 2012; 22:415–418. 68. Ko YH, et al. Short-­term testosterone augmentation in male schizophrenics: a randomized, double-­blind, placebo-­controlled trial. J Clin Psychopharmacol 2008; 28:375–383. 69. Zhang ZJ, et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-­resistant schizophrenia: a double-­blind, randomized, placebo-­controlled study. Schizophr Res 2006; 88:102–110. 70. Khodaie-­Ardakani MR, et al. Granisetron as an add-­on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-­blind placebo-­controlled study. J Psychiatr Res 2013; 47:472–478. 71. Salehi A, et al. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: a randomized, double-­blinded, placebo-­controlled trial. Psychiatry Res 2022; 316:114737. 72. Bugarski-­Kirola D, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-­ controlled trial in North America and Europe. Lancet Psychiatry 2022; 9:46–58. 73. Davis J, et al. Evaluating pimavanserin as a treatment for psychiatric disorders: a pharmacological property in search of an indication. Expert Opin Pharmacother 2021; 22:1651–1660. 74. Davidson M, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull 2022; 48:609–619. 75. Romeo B, et al. Efficacy of 5-­HT2A antagonists on negative symptoms in patients with schizophrenia: a meta-­analysis. Psychiatry Res 2023; 321:115104. 76. Ritsner MS, et al. Pregnenolone treatment reduces severity of negative symptoms in recent-­onset schizophrenia: an 8-­week, double-­blind, randomized add-­on two-­center trial. Psychiatry Clin Neurosci 2014; 68:432–440. 77. Brand BA, et al. The direct and long-­term effects of raloxifene as adjunctive treatment for schizophrenia-­spectrum disorders: a double-­blind, randomized clinical trial. Schizophr Bull 2023; 49:1579–1590. 78. Behdani F, et al. Can levetiracetam improve clinical symptoms in schizophrenic patients? A randomized placebo-­controlled clinical trial. Int Clin Psychopharmacol 2022; 37:159–165. 79. Kruiper C, et al. Clonidine augmentation in patients with schizophrenia: a double-­blind, randomized placebo-­controlled trial. Schizophr Res 2023; 255:148–154. 80. Hosseininasab M, et al. Nanocurcumin as an add-­on to antipsychotic drugs for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-­blind, placebo-­controlled study. J Clin Psychopharmacol 2021; 41:25–30. 81. Kaul I, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-­trospium) in schizophrenia (EMERGENT-­2) in the USA: results from a randomised, double-­blind, placebo-­controlled, flexible-­dose phase 3 trial. Lancet 2024; 403:160–170. 82. Li M, et al. Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2022; 272:633–642. 83. Yi S, et al. Efficacy of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms and cognitive functioning in schizophrenia: an umbrella review of systematic reviews and meta-­analyses. Psychiatry Res 2024; 333:115728. 84. Mondino M, et al. Transcranial direct current stimulation for the treatment of refractory symptoms of schizophrenia. Current evidence and future directions. Curr Pharm Des 2015; 21:3373–3383. 85. Kim J, et  al. A meta-­analysis of transcranial direct current stimulation for schizophrenia: ‘is more better?’ J Psychiatr Res 2019; 110:117–126. 86. Galderisi S, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry 2021; 64:e21. 87. Valiengo L, et al. Efficacy and safety of transcranial direct current stimulation for treating negative symptoms in schizophrenia: a randomized clinical trial. JAMA Psychiatry 2020; 77:121–129. 88. Potvin S, et al. A meta-­analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 2006; 36:431–440. 89. Arndt S, et al. Comorbidity of substance abuse and schizophrenia: the role of pre-­morbid adjustment. Psychol Med 1992; 22:379–388. 90. Leeson VC, et al. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-­episode schizophrenia. Schizophr Bull 2012; 38:873–880. 91. Barnes T, et al. Evidence-­based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharm 2020; 34:3–78.

No comments to display

Back to top